Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Biotin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | IDE | P14735 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | DUT | P33316 | 4/20 | 0.44 |
| ▸ | F2 | P00734 | 4/20 | 0.42 |
| ▸ | HLCS | P50747 | 2/20 | 0.39 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biotin SCHEMBL381578 | 0.88 | DUT (0.52) | TDP1DUTF2 | |
| SCHEMBL2808581 | 0.85 | F2 (0.51) | TDP1MEN1ABL1LMNAPKM | |
| Doxribtimine SCHEMBL4277671 | 0.83 | TDP1 (0.52) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL4304275 | 0.82 | TDP1 (0.44) | TDP1MEN1ABL1LMNAPKM | |
| Deoxyuridine SCHEMBL3709892 | 0.78 | DUT (0.64) | LMNADUT | |
| Deoxyuridine SCHEMBL15199 | 0.78 | DUT (0.64) | LMNADUT | |
| Deoxyuridine SCHEMBL20585969 | 0.78 | DUT (0.64) | LMNADUT | |
| Deoxyuridine SCHEMBL27615744 | 0.78 | DUT (0.64) | LMNADUT | |
| Deoxyuridine SCHEMBL1501332 | 0.78 | DUT (0.64) | LMNADUT | |
| Deoxyuridine SCHEMBL157130 | 0.78 | DUT (0.64) | LMNADUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170008940-A1 | Mucin Derived Polypeptides | MuciMed, Inc. | 2017-01-12 | — | — | US | disclosed |
| US-9119869-B2 | Mucin derived polypeptides | MUCIMED, INC, | 2015-09-01 | — | — | US | disclosed |
| US-20130345073-A1 | USE OF ALPHA-2-MACROGLOBULIN FOR DETERMINING OSTEONECROSIS DISEASE STATUS AND FOR SCREENING THERAPEUTIC AGENTS FOR PREVENTING OR TREATING OSTEONECROSIS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2013-12-26 | — | — | US | disclosed |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120028911-A1 | Mucin Derived Polypeptides | MuciMed, Inc. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110190399-A1 | CURCUMIN NANOPARTICLES AND METHODS OF PRODUCING THE SAME | Kar, Santosh Kumar (IN) | 2011-08-04 | — | — | US | disclosed |
| EP-2349237-A2 | CURCUMIN NANOPARTICLES AND METHODS OF PRODUCING THE SAME | Kar, Santosh Kumar (IN) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010129954-A1 | TREATMENT OF ISCHEMIA-REPERFUSION INJURY | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010013224-A2 | CURCUMIN NANOPARTICLES AND METHODS OF PRODUCING THE SAME | KAR SANTOSH KUMAR (IN) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | SPHK1, SPHK2, S1PR2 | TDP1 4199/4885MEN1 4490/4885ABL1 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.